Last Updated on October 15, 2024 by The Health Master
The US Food and Drug Administration (USFDA) approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol by Mylan Pharma for the treatment of two common pulmonary health conditions:
- Asthma in patients six years of age and older;
- The maintenance treatment of airflow obstruction and reducing exacerbations for patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and/or emphysema.
In a statement, USFDA said that this drug-device combination product is a Metered-Dose Inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing).
Two inhalations, two times a day (usually morning and night, about 12 hours apart), treat both diseases by preventing symptoms, such as wheezing for those with asthma, and by helping with better breathing, for those with COPD.
The inhaler is approved for two strengths (160/4.5 mcg/actuation and 80/4.5 mcg/actuation).
This approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market.
It can improve quality of life and help reduce the cost of treatment…….,” said Sally Choe, PhD, Director, Office of Generic Drugs, Center for Drug Evaluation and Research (CDER), FDA, in the statement.
It also said that the most common side effects associated with budesonide and formoterol fumarate dihydrate oral inhalation aerosol for those with asthma are:
- Nasopharyngitis (swelling of nasal passages and back of throat),
- Headache,
- Upper respiratory tract infection,
- Pharyngolaryngeal (nose and mouth) pain,
- Sinusitis,
- Influenza,
- Back pain,
- Nasal congestion,
- Stomach discomfort,
- Vomiting,
- Oral candidiasis (thrush).
For those with COPD, the most common side effects are nasopharyngitis, oral candidiasis, bronchitis, sinusitis and upper respiratory tract infection.
USFDA gives nod to Lupin for Vigabatrin for Oral Solution
USFDA gives tentative nod to Alembic for Macitentan Tablets 10 mg
USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets
USFDA gives nod to Strides Pharma for Colchicine tablets
USFDA gives nod to Alembic Pharmaceuticals for anti fungal drug
USFDA gives nod to Aleor for Nystatin and Triamcinolone Acetonide Ointment
Govt selects 3 Agencies to conduct study in Pharma and Medical…
USFDA gives nod to Lupin for Vigabatrin for Oral Solution
Availability of drugs at reasonable price: NPPA
Medical Device testing on patients not soon
Demand for framing of statutory working rules in Pharma industry
Drug recall: Fresenius Kabi recalled Sodium Acetate Injection, USP Due to…
USFDA complete audit of Granules Pharmaceuticals with 3 observations
USFDA gives tentative nod to Alembic for Macitentan Tablets 10 mg
Govt releases draft National Medical Device Policy 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
